Covidien plc Downgraded to “Neutral” at BTIG Research (COV)
COV has been the subject of a number of other recent research reports. Analysts at Raymond James downgraded shares of Covidien plc from a “strong-buy” rating to an “outperform” rating in a research note on Friday. They now have a $97.00 price target on the stock. Separately, analysts at Leerink Swann downgraded shares of Covidien plc from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, analysts at Leerink Partners downgraded shares of Covidien plc from an “outperform” rating to a “market perform” rating in a research note on Monday. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $81.70.
In other Covidien plc news, Insider Jose E. Almeida unloaded 51,166 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $92.05, for a total value of $4,709,830.30. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Covidien plc (NYSE:COV) opened at 91.18 on Friday. Covidien plc has a 52-week low of $55.3369 and a 52-week high of $92.68. The stock has a 50-day moving average of $76.40 and a 200-day moving average of $71.30. The company has a market cap of $41.111 billion and a P/E ratio of 26.09.
Covidien plc (NYSE:COV) last posted its quarterly earnings results on Friday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.01. The company had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.61 billion. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, analysts predict that Covidien plc will post $3.99 earnings per share for the current fiscal year.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.